Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership
Fifty1 AI Labs (OTC: FITY) has successfully completed the REVIVE Phase III clinical trial for Long COVID treatment, marking a significant breakthrough in AI-driven drug repurposing. The trial, conducted in collaboration with prestigious institutions including Stanford and Duke University, enrolled over 600 participants globally and represents the largest Long COVID study to date.
The company aims to achieve a $50 million valuation while targeting the $320.6 billion functional medicine market. The trial's success is powered by Fifty1's proprietary Bayesian and Predictive Platform, developed through a $1 million R&D investment. The company plans to uplist to OTCQB by Q1 2026 and eventually to NASDAQ, with upcoming product launches and a virtual shareholder teleconference scheduled for July 28, 2025.
Fifty1 AI Labs (OTC: FITY) ha completato con successo la sperimentazione clinica di fase III REVIVE per il trattamento del Long COVID, segnando un importante progresso nel riutilizzo di farmaci guidato dall'intelligenza artificiale. Lo studio, realizzato in collaborazione con prestigiose istituzioni come Stanford e Duke University, ha coinvolto oltre 600 partecipanti a livello globale ed è il più grande studio sul Long COVID finora condotto.
L'azienda punta a raggiungere una valutazione di 50 milioni di dollari mirando al mercato della medicina funzionale da 320,6 miliardi di dollari. Il successo della sperimentazione è supportato dalla piattaforma proprietaria Bayesiana e Predittiva di Fifty1, sviluppata grazie a un investimento in R&S di 1 milione di dollari. La società prevede di passare all'OTCQB entro il primo trimestre del 2026 e successivamente al NASDAQ, con il lancio di nuovi prodotti e una teleconferenza virtuale per gli azionisti programmata per il 28 luglio 2025.
Fifty1 AI Labs (OTC: FITY) ha completado con éxito el ensayo clínico de fase III REVIVE para el tratamiento de Long COVID, marcando un avance significativo en la reutilización de fármacos impulsada por inteligencia artificial. El estudio, realizado en colaboración con prestigiosas instituciones como Stanford y la Universidad de Duke, incluyó a más de 600 participantes a nivel mundial y representa el mayor estudio sobre Long COVID hasta la fecha.
La empresa aspira a alcanzar una valoración de 50 millones de dólares mientras apunta al mercado de la medicina funcional de 320.6 mil millones de dólares. El éxito del ensayo se basa en la plataforma bayesiana y predictiva propietaria de Fifty1, desarrollada mediante una inversión en I+D de 1 millón de dólares. La compañía planea ascender al OTCQB para el primer trimestre de 2026 y eventualmente al NASDAQ, con próximos lanzamientos de productos y una teleconferencia virtual para accionistas programada para el 28 de julio de 2025.
Fifty1 AI Labs (OTC: FITY)� 장기 코로� 치료� 위한 REVIVE 3� 임상시험� 성공적으� 완료하며 AI 기반 약물 재활� 분야에서 중요� 돌파구를 마련했습니다. 스탠포드와 듀� 대� � 명문 기관들과 협력하여 � 세계 600� 이상� 참가�� 대상으� 진행� 이번 임상시험은 지금까지 가� � 장기 코로� 연구입니�.
사� 5천만 달러 평가� 달성� 목표� 하며 3,206� 달러 규모� 기능� 의학 시장� 겨냥하고 있습니다. 이번 임상 성공은 100� 달러� 연구개발 투자� 개발� Fifty1� 독자적인 베이지� � 예측 플랫폼에 기반합니�. 사� 2026� 1분기까지 OTCQB� 상장 이전� 계획하고 있으�, 이후 NASDAQ 상장� 추진 중입니다. 신제� 출시와 2025� 7� 28� 예정� 가� 주주 전화회의� 준비하� 있습니다.
Fifty1 AI Labs (OTC : FITY) a réussi à terminer l'essai clinique de phase III REVIVE pour le traitement du Long COVID, marquant une avancée majeure dans le repositionnement de médicaments assisté par intelligence artificielle. L'essai, réalisé en collaboration avec des institutions prestigieuses telles que Stanford et l'Université Duke, a recruté plus de 600 participants à l'échelle mondiale et constitue la plus grande étude sur le Long COVID à ce jour.
L'entreprise vise une valorisation de 50 millions de dollars tout en ciblant le marché de la médecine fonctionnelle de 320,6 milliards de dollars. Le succès de l'essai repose sur la plateforme bayésienne et prédictive propriétaire de Fifty1, développée grâce à un investissement en R&D de 1 million de dollars. La société prévoit de passer à l'OTCQB d'ici le premier trimestre 2026, puis éventuellement au NASDAQ, avec des lancements de produits à venir et une téléconférence virtuelle pour les actionnaires prévue le 28 juillet 2025.
Fifty1 AI Labs (OTC: FITY) hat die REVIVE Phase-III-Studie zur Behandlung von Long COVID erfolgreich abgeschlossen und damit einen bedeutenden Durchbruch im KI-gesteuerten Drug Repurposing erzielt. Die Studie wurde in Zusammenarbeit mit renommierten Institutionen wie Stanford und der Duke University durchgeführt, umfasste über 600 Teilnehmer weltweit und ist die bislang größte Long-COVID-Studie.
Das Unternehmen strebt eine Bewertung von 50 Millionen US-Dollar an und fokussiert sich auf den 320,6 Milliarden US-Dollar großen Markt der funktionellen Medizin. Der Erfolg der Studie basiert auf Fifty1s proprietärer Bayesscher und prädiktiver Plattform, die durch eine F&E-Investition von 1 Million US-Dollar entwickelt wurde. Das Unternehmen plant, bis zum ersten Quartal 2026 an das OTCQB zu wechseln und später an die NASDAQ zu gehen, mit bevorstehenden Produkteinführungen und einer virtuellen Aktionärstelefonkonferenz am 28. Juli 2025.
- Successful completion of Phase III REVIVE trial - the largest Long COVID study to date with 600+ participants
- Strategic positioning in $320.6B functional medicine market with 13.8% CAGR
- $1M R&D investment in proprietary AI platform showing successful results
- Clear uplisting strategy to OTCQB (Q1 2026) and NASDAQ
- Planned strategic acquisitions in $5-10M range to enhance R&D capabilities
- Currently trading on OTC markets, indicating higher risk profile
- Significant capital requirements needed for planned acquisitions and R&D expansion
- Trial results still under peer review, pending final validation
- Website and product offerings not yet launched, indicating early-stage development
Pioneering a New Era in Healthcare: AI-Driven Innovation Unlocks Transformative Therapies and Drives Path to
SEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University (Canada), and global partners, proudly announces the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967). This historic Phase III, multicenter, adaptive, randomized, double-blind, placebo-controlled trial, the largest and most rigorous Long COVID study to date, marks a pivotal milestone in addressing a global health crisis affecting approximately 400 million people and
A Landmark Achievement in Long COVID Research and Functional Medicine
The REVIVE Trial is the first adaptive platform trial to demonstrate a clear treatment benefit for Long COVID, leveraging repurposed medicines to address this debilitating condition. This breakthrough aligns seamlessly with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting high-growth areas like preventative healthcare within the
Unprecedented Scale, Speed, and Scientific Excellence
As the largest completed Long COVID trial, REVIVE enrolled over 600 participants across multiple global sites, achieving the fastest recruitment of any study of its kind. This feat was made possible through Fifty1 AI Labs' operational excellence and strategic partnerships with world-class institutions, guided by the company's elite management team. The trial's rigorous execution and robust data collection underscore Fifty 1 Labs, Inc.'s commitment to scientific excellence and operational efficiency, key pillars of its Game Plan to enhance shareholder visibility and liquidity through uplisting and strategic growth initiatives.
Powered by Fifty1 AI Labs' Cutting-Edge AI Platform
The REVIVE Trial's success is driven by Fifty1 AI Labs' proprietary Bayesian and Predictive Platform, a cornerstone of Fifty 1 Labs, Inc.'s
Catalyzing Transformative Therapies and Intellectual Property Growth
The REVIVE Trial's findings, currently under peer review at a leading medical journal, establish a foundation for polypharmacy-based treatment regimens using repurposed drugs delivered through innovative systems such as transdermal and sublingual formulations. These advancements unlock significant opportunities for intellectual property (IP) development, enabling Fifty 1 Labs, Inc. to build a robust portfolio of proprietary therapeutic platforms. By securing IP rights and developing commercially viable products, the company is poised to capture a substantial share of the Long COVID treatment market, projected to generate billions in annual revenue. This strategic focus on IP and commercialization aligns with Fifty 1 Labs, Inc.'s Game Plan to pursue strategic acquisitions in the
"The REVIVE Trial is a testament to our vision of transforming healthcare through AI-driven innovation," said Dr. Paul Arora, CEO of Fifty 1 Labs, Inc. "By leveraging Fifty1 AI Labs' cutting-edge platform and our world-class partnerships, we are delivering hope to millions affected by Long COVID while creating a scalable model for future breakthroughs in functional medicine. Our Game Plan positions FITY to lead the biotech industry, driving exponential growth and exceptional returns for our shareholders."
Strategic Outlook: A Roadmap for Global Leadership
The REVIVE Trial's success is a critical step in Fifty 1 Labs, Inc.'s Game Plan to achieve a
For More Information
To learn more about Fifty 1 Labs, Inc., Fifty1 AI Labs, LLC, or the REVIVE Trial, visit or contact . Join us for the Virtual Shareholder Teleconference on X (@Fifty1Labs) on July 28, 2025, at 4:00 PM EST to hear directly from our leadership team.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. (OTC: FITY), a Nevada-based biotech pioneer, is transforming healthcare through AI-driven drug repurposing and functional medicine. Through its subsidiaries, the company delivers innovative, data-driven solutions for preventative healthcare and performance nutrition. Committed to revolutionizing personalized medicine, Fifty 1 Labs is poised to lead the biotech and wellness industries, creating lasting value for shareholders through cutting-edge innovation and strategic growth.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, and expectations regarding future events or performance. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
Email:
Phone: (877) 505-5006
Website:
